Compare ADMA Biologics Inc (ADMA) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while YieldMax MSTR Option Income Strategy ETF trades at $12.96. The key difference: ADMA Biologics Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ADMA | MSTY | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $114.30 |
52-Week Low | $7.60 | $11.55 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
MSTY trades at $13.64, up 0.44% today, with a bearish technical outlook indicated by moving averages and ADX signals. The ETF generates weekly dividends but faces significant price erosion, down over 75% from prior levels. Recent news highlights concerns about uncapped losses despite high distributions, with performance heavily tied to underlying Strategy (MSTR) stock volatility.
The outlook remains risky due to structural erosion of NAV from distributions, reliance on volatile option premiums, and negative sentiment. While high yields attract income seekers, total returns have been negative, emphasizing caution. Key risks include Strategy stock performance, unsustainable payout funding, and market skepticism about long-term viability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
